A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab...
-
Upload
loren-jones -
Category
Documents
-
view
224 -
download
3
Transcript of A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab...
A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion
of Chemotherapy with Bevacizumab for 1st-line Treatment of Locally-advanced, Recurrent, or
Metastatic Non-small Cell Lung Cancer (NSCLC)
Background & Rationale
Adapted from: 1Sandler A, et al., N Engl J Med 2006; 2Shepherd FA, et al., N Engl J Med 2005; 3Ciuleanu T, et al., ASCO 2008; 4Herbst RS, et al., J Clin Oncol 2007; 5Hainsworth J, et al., IASLC 2008.
ATLAS Study Design
Carboplatin/paclitaxel; cisplatin/vinorelbine; carboplatin or cisplatin/gemcitabine; carboplatin or cisplatin/docetaxel.
ATLAS Objective
ATLAS: Randomized Patients by Region
ATLAS Statistical Considerations
ATLAS: Analysis Populations
<2% of patients were lost to follow-up or withdrew consent.
As of data cutoff date: 18 July 2008.
*The randomized safety population consists of all randomized patients who received at least one dose of bevacizumab, erlotinib or placebo during the post-chemotherapy phase.
ATLAS: Baseline Characteristics (ITT population)
*Patients randomized as of July 18, 2008.
ATLAS: Baseline Characteristics (cont.)
ATLAS Efficacy Results
ATLAS: Progression-free Survival(ITT population, investigator assessment)
ATLAS: Additional PFS Outcome Measures(ITT population)
ATLAS: Progression-free Survival in Subgroups
*Includes <1% patients with ECOG PS 2.
ATLAS: Progression-free Survival in Subgroups(ITT population)
ATLAS: Preliminary Analysis of Subsequent Therapies Received (ITT population)
*Pemetrexed was most commonly used.
ATLAS Safety Results
ATLAS: Summary for Post Chemotherapy Treatment Phase (Safety population)
Formal statistical comparison testing between treatment arms was not done.
ATLAS: Causes of Death (Safety population)
*Other causes of death reported by investigators: carcinomatous meningitis, breast cancer, respiratory failure, unexplained pneumonia.
ATLAS: Adverse Events of Special Interest during the Post-chemotherapy Phase (Safety population)
Grade 5 events: Bevacizumab + Placebo: 1 (0.3%) CHF; Bevacizumab + Erlotinib: 2 (0.5%) Cardiovascular other than HTN, 1 (0.3%) ATE; 1 (0.3%) VTE.
ATLAS: Adverse Events of Special Interest (Cont.)
Grade 5 events: Bevacizumab + Placebo: 1 (0.3%) infection.
*Renal failure and hepatic events were reversible.
ATLAS Conclusions & Next Steps